David Risinger
Stock Analyst at Leerink Partners
(4.55)
# 223
Out of 5,182 analysts
181
Total ratings
66%
Success rate
16.44%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRAX First Tracks Biotherapeutics | Initiates: Outperform | $46 | $18.10 | +154.14% | 1 | Apr 24, 2026 | |
| CNTA Centessa Pharmaceuticals | Downgrades: Market Perform | $36 → $40 | $39.51 | +1.24% | 3 | Apr 1, 2026 | |
| ORKA Oruka Therapeutics | Maintains: Outperform | $58 → $86 | $76.39 | +12.58% | 3 | Mar 16, 2026 | |
| AMGN Amgen | Maintains: Outperform | $305 → $355 | $340.18 | +4.36% | 6 | Feb 4, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Outperform | $54 → $60 | $57.78 | +3.84% | 5 | Jan 13, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintains: Outperform | $456 → $525 | $426.01 | +23.24% | 6 | Dec 29, 2025 | |
| ROIV Roivant Sciences | Maintains: Outperform | $29 → $32 | $27.85 | +14.90% | 6 | Dec 15, 2025 | |
| XOMA XOMA Royalty | Maintains: Outperform | $58 → $45 | $41.97 | +7.22% | 1 | Dec 11, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Outperform | $886 → $1,104 | $868.27 | +27.15% | 17 | Nov 10, 2025 | |
| IMA ImageneBio | Initiates: Outperform | $30 | $5.83 | +414.58% | 1 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | $70 | $64.49 | +8.54% | 4 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $169 → $153 | $225.34 | -32.10% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $762 → $834 | $744.44 | +12.03% | 9 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $206 | $197.38 | +4.37% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $69 | $28.75 | +140.00% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $15.11 | +5.89% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $59.72 | +156.20% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $16.81 | -40.51% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $66.59 | -29.42% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $127.75 | -28.77% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $26.79 | +79.17% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $13.16 | +181.16% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $201.22 | -12.53% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $14.81 | +8.04% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $11.49 | +291.64% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $5.58 | +527.24% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $22.09 | +85.60% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $117.87 | +47.62% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $49.65 | +2.72% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $31.26 | -74.41% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $110.23 | -19.26% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $12.57 | -76.13% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $33.73 | -52.56% | 9 | Apr 2, 2020 |
First Tracks Biotherapeutics
Apr 24, 2026
Initiates: Outperform
Price Target: $46
Current: $18.10
Upside: +154.14%
Centessa Pharmaceuticals
Apr 1, 2026
Downgrades: Market Perform
Price Target: $36 → $40
Current: $39.51
Upside: +1.24%
Oruka Therapeutics
Mar 16, 2026
Maintains: Outperform
Price Target: $58 → $86
Current: $76.39
Upside: +12.58%
Amgen
Feb 4, 2026
Maintains: Outperform
Price Target: $305 → $355
Current: $340.18
Upside: +4.36%
Bristol-Myers Squibb Company
Jan 13, 2026
Maintains: Outperform
Price Target: $54 → $60
Current: $57.78
Upside: +3.84%
Vertex Pharmaceuticals
Dec 29, 2025
Maintains: Outperform
Price Target: $456 → $525
Current: $426.01
Upside: +23.24%
Roivant Sciences
Dec 15, 2025
Maintains: Outperform
Price Target: $29 → $32
Current: $27.85
Upside: +14.90%
XOMA Royalty
Dec 11, 2025
Maintains: Outperform
Price Target: $58 → $45
Current: $41.97
Upside: +7.22%
Eli Lilly and Company
Nov 10, 2025
Upgrades: Outperform
Price Target: $886 → $1,104
Current: $868.27
Upside: +27.15%
ImageneBio
Oct 24, 2025
Initiates: Outperform
Price Target: $30
Current: $5.83
Upside: +414.58%
Oct 14, 2025
Upgrades: Market Perform
Price Target: $70
Current: $64.49
Upside: +8.54%
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $225.34
Upside: -32.10%
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $744.44
Upside: +12.03%
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $197.38
Upside: +4.37%
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $28.75
Upside: +140.00%
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $15.11
Upside: +5.89%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $59.72
Upside: +156.20%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $16.81
Upside: -40.51%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $66.59
Upside: -29.42%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $127.75
Upside: -28.77%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $26.79
Upside: +79.17%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $13.16
Upside: +181.16%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $201.22
Upside: -12.53%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $14.81
Upside: +8.04%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $11.49
Upside: +291.64%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $5.58
Upside: +527.24%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $22.09
Upside: +85.60%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $117.87
Upside: +47.62%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $49.65
Upside: +2.72%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $31.26
Upside: -74.41%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $110.23
Upside: -19.26%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $12.57
Upside: -76.13%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $33.73
Upside: -52.56%